Theme: Accelerating Innovations and New Challenges in Vaccines and Vaccination

Euro Vaccines-2015

Renowned Speakers

Euro Vaccines-2015

vaccine is a biological preparation that provides active acquired immunity to a particular disease.Vaccinology is a major field in eradication of diseases. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases.

The International Conference Eurovaccines-2015 will focus on the Human vaccines, Veterinary vaccines, Novel Approaches in Design of Cellular and Molecular-Based Vaccines, Modern Technologies in Vaccine Discovery and Development, Vaccines against Infectious Diseases and Cancers, Manufacturing, Production, and Development of Vaccines, Vaccine safety

 Eurovaccines conference serves as an International forum to bring participants close to key professionals to promote mutual understanding and to accelerate research in the field, enabling the medical community to provide ultimate care to the patients.

 

Vaccines Business tripled in value from USD 5B in 2000 to almost USD 24 B in 2013, Global market projected to rise to USD 100 B by 2025. More than 120 new products in the development pipeline. 60 are of importance for developing countries. UNICEF had a market of 1,03 B$ in 2011, PAHO had 400 million dollars in 2011 and total UN market of 340 million dollars in 2002,  1,430 billion dollars in 2011 the vaccines business meetings will strengthen global network with the leaders.

With an intention to explore the current Global research in  vaccines OMICS international initiated to organize Euro Global Summit and Expo on Vaccines & Vaccination to be held at Birmingham UK during August 17-19, 2015.

 

 

 

 

 

 

I am pleased to announce the “6thEuro Global Summit and Expo on Vaccines & Vaccination” (Euro vaccines-2015) to be held in Birmingham, UK, August 17- 19, 2015, with the OMICS International as conference Organizer. This follows the success of the Vaccines-2013 meeting in Las Vegas and the Vaccines-2014 meeting recently held in Valencia, Spain.

The theme of Euro vaccines -2015 will be “Accelerating Innovations and New Challenges in Vaccines and Vaccination”. This annual vaccine summit, which for the first time is being held in Birmingham, will bring together vaccine researchers, postdoctoral fellows, students, clinicians, epidemiologists, public health professionals and industry representatives from around the world, providing them with the opportunity to report and discuss important scientific challenges and achievements in the vaccine field. Most importantly it will provide great opportunities for creation of new collaborations and linkages between academics, clinicians and industry. Such partnerships will be critical to translation of recent laboratory break throughs into the vaccines of tomorrow. Examples of the diverse topics that will be covered in this comprehensive conference include; vaccine antigen discovery, design, manufacture and formulation, animal models, human clinical trials, correlates of vaccine protection, novel delivery technologies, vaccine adjuvants, mucosal immunology, innate immune pathways, T- and B-cell immunology, veterinary vaccines, DNA and RNA vaccines, live vectors, vaccine side effects, epidemiology and immunotherapy, amongst many others. Vaccine areas to be covered will include infectious disease, cancer, autoimmunity, Alzheimer’s disease and allergy. The meeting will focus on both basic immune mechanism studies and clinical vaccine advances. Through attendance at Euro vaccines -2015, you will be able to share your research results with your colleagues and have opportunities to establish new academic and industry collaborations. We will also invite those presenting at Vaccines-2015 the opportunity to publish a manuscript from their talk in the Journal of Vaccines and Vaccination. Please consider joining us in Birmingham UK for an exciting vaccine meeting.

Do not hesitate to get in touch with me if you have any suggestions or questions regarding the organization of this meeting.

Professor Nikolai Petrovsky

 

President Euro Vaccines-2015

Editor-in-Chief, Journal of Vaccines and Vaccination

Research Director, Vaxine Pty Ltd

Flinders Medical Centre/Flinders University, Adelaide

"Vaccines Aisa Pacific-2015 Organizing Committee" congratulates our previous conference best poster award winners and Young Researcher Award winners. 

4th International Conference on Vaccines & Vaccination, September 24-26, 2014 Valencia, Spain

  • Rong Xu, Cardiff University, UK

Title: IL-34 suppresses Candida albicans induced TNF-α production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression

  • Daisy Vanrompay, Ghent University, Belgium
          Title: Protection of chickens against Chlamydia psittaci challenge by  mucosal immunization with the major outer membrane               protein
  • Silvia Vendetti, Istituto Superiore di Sanita, Italy
          Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic                         boosting in mice
- See more at: http://vaccines.global-summit.com/asia-pacific/#sthash.pXrHfEnf.dpuf

"Vaccines Aisa Pacific-2015 Organizing Committee" congratulates our previous conference best poster award winners and Young Researcher Award winners. 

4th International Conference on Vaccines & Vaccination, September 24-26, 2014 Valencia, Spain

  • Rong Xu, Cardiff University, UK

Title: IL-34 suppresses Candida albicans induced TNF-α production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression

  • Daisy Vanrompay, Ghent University, Belgium
          Title: Protection of chickens against Chlamydia psittaci challenge by  mucosal immunization with the major outer membrane               protein
  • Silvia Vendetti, Istituto Superiore di Sanita, Italy
          Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic                         boosting in mice
- See more at: http://vaccines.global-summit.com/asia-pacific/#sthash.pXrHfEnf.dpuf

"Euro Vaccines -2015 Organizing Committee" congratulates our previous conference best poster award winners and Young Researcher Award winners. 

4th International Conference on Vaccines & Vaccination, September 24-26, 2014 Valencia, Spain

  • Rong Xu, Cardiff University, UK

Title: IL-34 suppresses Candida albicans induced TNF-α production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression

  • Daisy Vanrompay, Ghent University, Belgium

          Title: Protection of chickens against Chlamydia psittaci challenge by Mucosal Immunization with the major outer membrane protein

  • Silvia Vendetti, Istituto Superiore di Sanita, Italy

          Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice. 

With the overwhelming success of previous annual Vaccines conferences, EuroVaccines-2015 organizing Committee welcomes to the Euro Global Summit and Expo on Vaccines & Vaccination, during August 17-19, 2015 in Birmingham, West Midlands, UK.

Major Symposia:

Round Table Session Cell mediated immune (CMI) monitoring and its challenges
What are the issues?
What readouts are used?
Are viable cells needed?
What are the best collection methods

Organizer:

Magdalena Tary-Lehmann

Chief Scientific Officer &
Co-Founder of Cellular Technology (CTL) Limited

 

Immune prevention of cancer with potential prophylactic vaccines

Organizer:

Michael G. Hanna

Founder, Chairman Emeritus
Vaccinogen Inc., USA

 

Immunoassays for wanted and unwanted immunogenicity including validation

Organizer:

Melody Sauerborn

Head of non-clinical development at Mymetics BV 

Netherlands

 

EuroVaccines-2015 hosting presentations from Global Leaders in the field across the Globe. And bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. In association with the Vaccines & Vaccination OMICS meeting there will be opportunities for those selected to present at the meeting to also publish a manuscripts and abstracts from their talk in the Journal of Vaccines and Vaccination or its sister publication Immunome Research.

Scientific Sessions:

Vaccines technology 

Prominent market players of vaccines technology  market are Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).

Preventable disease vaccines

The use of preventable vaccines is to avoid the occurrence of an infectious disease, which is preventable by the use of vaccines. TechNavio's analysts forecast the Global Preventable Vaccines market to grow at a CAGR of 10.16 percent over the period 2014-2019. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Topics related to vaccines development and vaccines safety will be covered by international speaker’s. This provide a forum for researchers, professionals and policy makers to present, share and exchange the latest cutting edge discoveries in vaccines and vaccinations. We hope to facilitate new collaborations between experts in the field and inspire new and innovative ideas in vaccine development.

Emerging diseases

Emerging infectious diseases represent a grave threat to animal and human populations in terms of their impact on global health, agriculture and the economy. Vaccines developed for emerging infections in animals can protect animal health and prevent transmission of zoonotic diseases to humans. The vaccine technology market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. Major factors driving growth of vaccine technology market include rising prevalence of diseases, increasing government initiatives for expanding immunization across the globe, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations.

Vaccines in Korea 

According to the Korea Health Industry Development Institute (KHIDI), the global vaccine market will grow by 11.5 percent for the next six years to US$56.7 billion by 2017, from US$31.7 billion in 2011. The government started to support the pharmaceutical industry by announcing the globalization of the vaccine business, which entails a national goal to become the world’s fifth vaccine country by 2020. Considering the technical capabilities and development stages in Korea, vaccine businesses are expected to grow the fastest in the biotech industry. The Ministry of Food and Drug Safety presented a plan to expand varieties of domestically-produced vaccines from 10 to 22 by 2020, in order to enhance the self-sufficiency of vaccine. Vaccines summit provide a forum for researchers, professionals and policy makers to present, share and exchange the latest cutting edge discoveries in vaccines and vaccinations. We hope to facilitate new collaborations between experts in the field and inspire new and innovative ideas in vaccine development.

Zoster vaccine conferences

Anyone who has had chicken pox is at risk for developing shingles. It is estimated that 1 million or more cases occur each year in the United States. Shingles can occur in people of all ages and the risk increases as people get older. When shingles develop, a rash or blisters appear on the skin, generally on one side of the body. This is a sign that the virus, that has been dormant in the nerve cells, has reactivated and travelled from the nerves and followed a path out to the skin. Because the nerves along the path become inflamed, shingles can also be painful. Pain that lasts for months after the rash has healed is called post herpetic neuralgia or PHN. For some people, this pain can be severe and chronic. Researchers found that overall (in persons age 60 years and older) the vaccine reduced the occurrence of herpes zoster (shingles) by about 50%. The vaccine effect was highest at 64% in people between the ages 60-69, but its effectiveness declined with increasing age; to 41% for the 70-79 age group, and 18% for those 80 years of age and older.

Veterinary vaccine:

The major goals of veterinary vaccines are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. successful veterinary vaccines have been produced against viral, bacterial, protozoa, and multicellular pathogens, which in many ways have led the field in the application and adaptation of novel technologies, These veterinary vaccines have had, and continue to have, a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases. The continued interaction between animals and human researchers and health professionals will be of major importance for adapting new technologies, providing animal models of disease, and confronting new and emerging infectious diseases.

Ebola vaccine:

Ebola haemorrhagic fever is a highly contagious disease that causes death in up to 90 percent of those infected with the virus. Furthermore, there is no treatment that will cure the infection once it begins; therefore, preventing the spread of the virus is crucial to containing outbreaks. This is one reason why research scientists are actively studying a possible Ebola vaccine. At this point, there is not a licensed vaccine for humans; however, an Ebola vaccine has shown to be effective in monkeys based on recent research findings, a single shot of a fast-acting, experimental vaccine successfully protected monkeys from the deadly Ebola virus after only one month. If this vaccine proves similarly effective in humans, it may one day allow scientists to quickly contain outbreaks with ring vaccination, which is the same strategy that was successfully used against smallpox, This research has enormous public health implications, not only because it might be used to limit the spread of Ebola virus, which continues to emerge in central Africa, but also because this vaccine strategy may be applied to other highly lethal viruses that cause acute disease outbreaks and require a rapid response such as the Marburg and Lassa fever viruses, and the severe acute respiratory syndrome (SARS) coronavirus.

HPV vaccine:

Human papillomaviruses (HPVs) are a group of more than 200 related viruses. More than 40 HPV types can be easily spread through direct sexual contact, from the skin and mucous membranes of infected people to the skin and mucous membranes of their partners. They can be spread by vaginal, anal, and oral sex. Other HPV types are responsible for non-genital warts, which are not sexually transmitted. Three vaccines are approved by the FDA to prevent HPV infection: Gardasil, Gardasil 9, and Cervix. All three vaccines prevent infections with HPV types 16 and 18, two high-risk HPVs that cause about 70 percent of cervical cancers and an even higher percentage of some of the other HPV-associated cancers. Gardasil also prevents infection with HPV types 6 and 11, which cause 90 percent of genital warts . Because Gardasil protects against infection with four HPV types, it is called a quadrivalent vaccine. Gardasil 9 prevents infection with the same four high-risk HPV types plus five additional high-risk HPV types and is therefore called a nonavalent, or 9-valent, vaccine. All three vaccines are given through a series of three injections into muscle tissue over a 6-month period.

Influenza Vaccine:

Influenza is a serious disease that can lead to hospitalization and sometimes even death. Every flu season is different, and influenza infection can affect people differently. Even healthy people can get very sick from the flu and spread it to others. Flu vaccines cause antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are in the vaccine. The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. Traditional flu vaccines (called trivalent vaccines) are made to protect against three flu viruses; an influenza A (H1N1) virus, an influenza A (H3N2) virus, and an influenza B virus. In addition, there are flu vaccines made to protect against four flu viruses (called “quadrivalent” vaccines). These vaccines protect against the same viruses as the trivalent vaccine and an additional B virus. Flu viruses are constantly changing (called “antigenic drift”) – they can change from one season to the next or they can even change within the course of one flu season. Experts must pick which viruses to include in the vaccine many months in advance in order for vaccine to be produced and delivered on time. 

Vaccines for unconventional Disease:

A vaccine-preventable disease is an infectious disease for which an efficacious preventive vaccine subsists. If a person acquires a vaccine-preventable disease and dies from it, the death is considered a vaccine-preventable death. The most mundane and solemn vaccine-preventable diseases tracked by the World Health Organization (WHO) are: diphtheria, Haemophilic influenza, serotype infection, hepatitis, measles, meningitis, mumps, pertussis, poliomyelitis, rubella, tetanus, tuberculosis, and yellow fever. The WHO reports licensed vaccines being available to obviate, or contribute to the aversion and control of, 25 vaccine-preventable infections. Vaccine-preventable deaths are conventionally caused by a failure to obtain the vaccine in a timely manner. This may be due to financial constraints or to lack of access to the vaccine. A vaccine that is generally recommended may be medically incongruous for a minuscule number of people due to astringent allergies or a damaged immune system.

Developing Next Generation Conjugate Medicine:

Conjugate vaccines are glycoprotein molecules (consisting of a protein and polysaccharide component linked together). These sugars are surface exposed bacterial antigens to which the body will develop an immune replication. The protein carrier is responsible for eliciting a perennial immune replication against the polysaccharide in adolescent children, leading to auspice against infection by the pathogen. The chemical conjugation process is non-concrete so that there is heterogeneity in the final product and batch-to-batch variability occurs. Pharmaceutical companies have made paramount strides in optimizing this process and consequential vaccines are available against pathogens such as Streptococcus pneumonia and MEN A and C. However, the chemistry-predicated process has not been able to tackle other paramount pathogens. Albeit the recombinant DNA approach has many advantages over the chemistry approach, evidence is required to show that safe and immunogenic vaccines can be developed and that the manufacturing process is scalable if a vaccine candidate reaches the market. Albeit there is a paramount amount of work still ahead afore a vaccine candidate is licensed for sale, vigorous evidence is accumulating that recombinant DNA-predicated conjugate vaccine development and manufacturing is a valid approach and that pathogens without available vaccines today are feasible targets.

 Developing Technology:

The ability to move genetic determinants between species using in vitro gene-manipulation techniques has opened up new approaches to vaccine development. This has rapidly grown into an exciting area of research in both academic and industrial laboratories. There are numerous scientific challenges which require multidisciplinary teams to solve problems in creating new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. What is apparent from the work carried out so far is that there are few easy answers to vaccine development and it is not realistic to expect rapid solutions to these problems.

Vaccines R&D:

Many organisations working on research, development and production in the field of vaccines. Eg- Crucell focuses on research & development, production and marketing of vaccines and antibodies against infectious diseases. With its current portfolio of vaccines, Crucell is working on hepatitis A/B, paediatric and respiratory infectious diseases and travellers’ diseases. One of its products is Quinvaxem, the first fully liquid vaccine against 5 children’s diseases (diphtheria, tetanus, whooping cough, hepatitis B and HIV). unicef has bought and distributed over 500 million dosages of this product. Crucell was acquired by Johnson & Johnson pharmaceuticals group in 2011. As a result, Crucell will now operate as the global centre for vaccines within J&J. Falco Biotherapeutics is building a product pipeline with drug candidates for the treatment of inflammatory disorders and infectious diseases by leveraging on the unique properties of ElCams TM - a new generation of novel therapeutic, diagnostic and prophylactic protein-based health care products. The company is also working on its Lactobacillus delivery technology. Mymetics focuses on the development of new generation mucosal and virosome-based vaccines.

New trend in carbohydrate based vaccines:

Glycomics is the study that deals with the structures and functions of carbohydrates. The revelation of novel and incrementing number of numerous biological roles of carbohydrates, glycomics has explored the field of carbohydrate vaccines. Tumour-associated carbohydrate antigens (TACAs) are paramount molecular markers on the cancer cell surface, utilizable for the development of therapeutic cancer vaccines or cancer immunotherapies. However, due to their poor immunogenicity and/or immunotolerance, most TACAs fail to induce T cell-mediated immunity that is critical for cancer therapy. This review summarizes the recent effort to surmount this quandary via constructing TACA conjugates with ameliorated immunogenicity, such as by covalently coupling TACAs to opportune carrier molecules to compose clustered or multi-epitopic conjugate vaccines, coupling TACAs to a T cell peptide epitope and/or an immunostimulant epitope to compose plenarily synthetic multi-component glycoconjugate vaccines, and developing vaccines predicated on chemically modified TACAs, which is cumulated with metabolic engineering of cancer cells.

For more scientific sessions, please follow: http://vaccines.global-summit.com/europe/call-for-abstracts.php

Experts outlook on our previous conferences

·Mahesh Mohan, Tulane University Health Science Center, USA
I enjoyed attending the vaccines business meeting and also had the opportunity to meet other researchers and learn about their research for future collaborations. The talks were informative and I had the opportunity to learn new information. Overall, I enjoyed the conference."

·Martin D'Souza, Mercer University, USA

Many thanks as well for organizing this very focused meetings on vaccines 

·De-Chu Christopher, International Vaccine Institute, Korea
Many thanks for organizing this great forum for brain storms to occur nonstop

· Donald E. Greydanus, Western Michigan University School of Medicine, USA
Thank you and I enjoyed the vaccines conference as well as the chance to meet with Dr. Gedela Babu to discuss various issues. I wish you continued success with your conferences!

·Hyunah Lee, Sungkyunkwan University School of Medicine, Korea
It was my great pleasure attending and presenting my paper at the Vaccines-2012. I am sure that the conference was successful. And your hospitality left me with deep impression.

For more relavant conferences, visit: http://conferenceseries.com/immunology-conferences.php 

 

 

The 4th International Conference on Vaccines & Vaccination, hosted by the OMICS International. It was held in

September 24-26, 2014 Valencia, Spain. Generous response and active participation was received from the Editorial

Board Members of OMICS International Journals as well as from scientists, researchers and leaders from Pharma, government organizations, students who made this conference as one of most successful and productive events in 2014 from OMICS International.Also, the conference was carried out through various sessions, in which the discussions were held on the following scientific tracks:

Overview

http://www.conferenceseries.com/immunology-conferences.php

• Vaccines and the Basic Immune System

• New Approaches for B and T Cells

• Cellular and Molecular-Based Vaccines

• Vaccines Against Infectious Diseases

• Manufacturing, Production and Development of Vaccines

• Regulatory and Ethical Issues of Vaccines and Public Acceptance

• Current Issues on Clinical Evaluation and Field Trials of Vaccines

• Modern Technologies in Vaccine Discovery and Development

• Age-Specific Immune Response to Vaccination

• Novel Delivery technologies in Vaccines and many more...

 

The response to 4th International Conference on Vaccines & Vaccination was huge and was attended by about

550 attendees representing 55 countries from different corners of the world.The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the keynote forum. The list included

 

Jeffrey B Ulmer, Novartis Vaccines USA

Ray Spier, Former President, International Society for Vaccines, UK

Michael G Hanna, CEO, Vaccinogen, Inc., USA and many more...

All the above mentioned Honorable Guests and keynote speakers gave their energetic and fruitful contributions

at Vaccines-2014.

 

All accepted abstracts have been indexed in OMICS International -Journal of Vaccines & Vaccination as a special issue. The theme of this Conference was on “Prospects and Development of Prophylactic & Therapeutic Vaccines”. Based on this, speaker’s discussions included many recommendations.

 

Conference Proceedings :

http://omicsonline.org/ArchiveJVV/vaccines-and-vaccination-2014-proceedings.php

 

Sponsors and exhibitors

Sanofi Pasteur SA

U.S. Headquarters, Discovery Drive, Swiftwater, PA 18370

Vaccinogen Inc.,

5300 West view Dr # 406, Frederick, MD 21703, United States

Cellular Technology Limited (CTL)

North & South America

CTL Headquarters, 20521 Chagrin Blvd., Shaker Heights, OH 44122-5350 USA,

Gen Phar

600 Seacoast Pkwy # 100,

Mt Pleasant, SC 29464, United States

OMICS International, the global leader in organizing annual “International conferences and Exhibitions on Vaccines and Vaccinations” The Annual Vaccines Conferences provides high-quality, current reports of scientific progress and best practices featured in both invited presentations and submitted oral abstracts and posters. The Global Vaccines Conferences and Expos organized by OMICS International, bring together the diverse disciplines involved in the research and development of vaccines and associated technologies for disease control through immunization. By drawing upon an global audience of CEOs, CSOs, scientists and researchers, healthcare professionalsand trainees, veterinarians, vaccine manufacturers, and public health officials, the conference is designed to encourage the exchange of ideas across a broad range of disciplines.

 

Highlights of Annual Global Vaccines Conferences-OMICS International

 

• Keynote forum

• Exhibitions

• Company Presentations

• Speaker Forum

• Workshops and Symposia’s

• B2B Meetings

• One to One meeting

• Special Session for Students

• Scientific writing

• Journal review

• Grant writing

• Strategies for building a scientific career

• Scientific careers outside of research

• Company Promotions

• Young Research Forum

• Best Poster Awards

• Certification by the “International Organizing committee” and many more...

The 2nd International Conference on Vaccines & Vaccination, hosted by the OMICS International . It was held in August 20-22, 2012 in Hilton Chicago/Northbook, USA. Generous response and active participation was received from the Editorial Board Members of OMICS International Journals as well as from scientists, researchers and leaders from Pharma, government organizations, students who made this conference as one of most successful and productive events in 2012 from OMICS International. Vaccines 2012 hosted 300+ attendees representing 55 countries from different corners of the world. The conference was carried out through various sessions, in which the discussions were held on the following

 

scientific tracks:

• Vaccines and the Basic Immune System

• New Approaches for B and T Cells

• Cellular and Molecular-Based Vaccines

• Vaccines Against Infectious Diseases

• Manufacturing, Production and Development of Vaccines

• Regulatory and Ethical Issues of Vaccines and Public Acceptance

• Current Issues on Clinical Evaluation and Field Trials of Vaccines

• Modern Technologies in Vaccine Discovery and Development

• Age-Specific Immune Response to Vaccination and many more...

 

Conference Proceedings:

http://omicsonline.org/ArchiveJVV/vaccines-vaccination-2012-proceedings.php

The response to 2nd International Conference on Vaccines & Vaccination was huge and was attended by about

300 attendies representing 25 countries from different corners of the world.The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the keynote forum. The list included

 

De-Chu Christopher Vaxin Inc., USA

John Dong GenPhar, USA

Donald E. GreydanusWestern Michigan University School of Medicine, USA

Eli Young OpSaniTx, USA

Takashi Kei Kishimoto Selecta Biosciences, USA

Daniel H Zimmerman CEL-SCI Corporation, USA

Gerardo Kaplan FDA, USA

Kei AmemiyaU.S. Army Medical Research Institute of Infectious Diseases, USA

HavalShirwanUniversity of Louisville, USA and many more...

All the above mentioned Honorable Guests and keynote speakers gave their energetic and fruitful contributions

at Vaccines-2012.All accepted abstracts have been indexed in OMICS International- Journal of Vaccines & Vaccination as a specialissue. The theme of this Conference was on “Prospects and Development of Prophylactic & Therapeutic Vaccines”. Based on this, speaker’s discussions included many recommendations.

The International Conference and Exhibition on Vaccines & Vaccination (Vaccines-2011) was held on November

22-24, 2011 in Philadelphia Airport Marriott Hotel, USA. This successful conference organized by OMICS Group brought together Medical Specialists, Researchers and Vaccine Developers who were delighted with the many speeches, presentations, and discussions, which demonstrated the determination to innovate and improve knowledge on Vaccines.Vaccines-2011, helped to open new ideas, advanced technologies, innovative approaches towards Vaccines. Several speakers from almost 30 countries have participated in this conference which was carried out through several sessions with the theme “Current Strategies in Vaccination”.

 

Conference highlighted the following topics:

• Vaccines and the basic immune system

• New approaches for B and T cells

• Cellular and molecular-based vaccines

• Vaccines against infectious diseases

• Therapeutic vaccine manufacturing, production and development

• Logical and ethical issues and vaccines

• Experimental and clinical evaluation of therapeutic vaccines

• Basic Vaccinology and modern vaccine discovery technologies and many more...

The Luxurious accommodation during the conference also created a relaxed and informal atmosphere with

aright setting for highly interactive sessions where the speakers shared the knowledge on current issues and

strategies of Vaccines and Vaccination.

We take an immense pleasure in thanking our Keynote Speakers:

Gary Alan Flory Virginia Department of Environmental Quality, USA

Gregory J. Tobin Biological Mimetics, Inc. (BMI), USA

Kei AmemiyaUS Army Medical Research Institute, USA

Edmund J. GosselinAlbany Medical College, USA

Mansour MohamadzadehUniversity of Florida, USA and many more...

 

Vaccines 2011 hosted 200+ attendees representing 30 countries from different corners of the world.

Conference Proceedings Vaccines-2011

We are grateful to all speakers, scientific societies, governmental and non-governmental institutions, Professors, scientists, representatives of patient groups from throughout the world for their commitment and the support. We would like to thank our organizing committee members for providing advice on the agenda, and in supporting the conference. We are grateful to NIH, GSK, Sanofi Pasture, and other sponsors for their invaluable support for the success of the event. Journal of Vaccines & Vaccination and Journal of Clinical & Cellular Immunology have published all papers presented at this meeting as a special issue. With the overwhelming response and suggestions and feedbacks from our previous attendees. OMICS International is organizing its Global Vaccines conferences in major countries across the globe: We are also obliged to various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Our sincere thanks to Organizing Committee Members for their gracious presence, support and assistance towards Vaccines-2012.

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date August 17-19, 2015
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View